DRUG · Unmapped registry intervention
[18F]NAV4694
Find medicine records ·
Find other trials using this name
Clinical trial
Beta-Amyloid Imaging With [18F]NAV4694 PET in Predicting Progression to AD in Subjects MCI
NCT01812213
Drugs and interventions used in this trial
1 registeredThese interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.
No matching interventions in this trial.
Study at a glance
Registry-backedBeta-Amyloid Imaging With [18F]NAV4694 PET in Predicting Progression to AD in Subjects MCI
Design: INTERVENTIONAL · Status: TERMINATED · Phase: PHASE2
Read study objectives, eligibility and outcome measures at ClinicalTrials.govAdvertisement
Conditions
Mild Cognitive Impairmentunresolved
Interventions
[18F]NAV4694DRUG
Sponsors & collaborators
Navidea Biopharmaceuticalslead sponsor
Mapped research locations
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT01812213 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.